Nautilus, Abcam form partnership

By The Science Advisory Board staff writers

November 2, 2021 -- Nautilus Biotechnology and Abcam have signed a strategic development and supply partnership agreement.

Under the new partnership, Abcam will provide its recombinant monoclonal antibody development technologies and expertise to enhance Nautilus' reagent research and development activities, according to the companies. A long-term supply relationship has also been established.

Initially, the partnership will focus on the collaborative development of affinity binding reagents for use on the Nautilus proteomic analysis system. The relationship will expand to large-scale manufacturing and the supply of reagents for commercialization, the companies said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.